MA58653A1 - USE OF A GLUTARIMIDE DERIVATIVE TO TREAT DISEASES RELATED TO ABERRANT INTERLEUKIN-6 ACTIVITY - Google Patents
USE OF A GLUTARIMIDE DERIVATIVE TO TREAT DISEASES RELATED TO ABERRANT INTERLEUKIN-6 ACTIVITYInfo
- Publication number
- MA58653A1 MA58653A1 MA58653A MA58653A MA58653A1 MA 58653 A1 MA58653 A1 MA 58653A1 MA 58653 A MA58653 A MA 58653A MA 58653 A MA58653 A MA 58653A MA 58653 A1 MA58653 A1 MA 58653A1
- Authority
- MA
- Morocco
- Prior art keywords
- activity
- aberrant
- interleukin
- diseases related
- treat diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
Abstract
La présente invention se rapporte au domaine de la médecine et concerne un traitement de maladies associées à une activité aberrante l'interleukine-6 et au développement du syndrome de libération de cytokines (choc cytokinique), de préférence un traitement du covid-19, ainsi que d'autres maladies compliquées par une activité aberrante d'interleukine-6 et le développement d'un syndrome de libération de cytokines, ceci en utilisant un composé de 1-(2-(1-méthyl-1?-imidazol-4- yl)éthyl)pipéridine-2,6-dione (i). L'invention permet de créer un nouvel agent médicamenteux efficace pour le traitement de maladies associées au développement du syndrome de libération de cytokines.The present invention relates to the field of medicine and relates to treatment of diseases associated with aberrant interleukin-6 activity and the development of cytokine release syndrome (cytokine shock), preferably treatment of covid-19, as well as other diseases complicated by aberrant interleukin-6 activity and the development of cytokine release syndrome, using a 1-(2-(1-methyl-1?-imidazol-4- yl)ethyl)piperidine-2,6-dione (i). The invention makes it possible to create a new medicinal agent effective for the treatment of diseases associated with the development of cytokine release syndrome.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2020121363A RU2774928C2 (en) | 2020-06-26 | Use of glutarimide derivative for therapy of diseases associated with aberrant activity of interleukin-6 | |
PCT/RU2021/050170 WO2021262040A1 (en) | 2020-06-26 | 2021-06-18 | Use of a glutarimide derivative for treating diseases associated with aberrant interleukin-6 activity |
Publications (2)
Publication Number | Publication Date |
---|---|
MA58653A1 true MA58653A1 (en) | 2023-07-31 |
MA58653B1 MA58653B1 (en) | 2024-02-29 |
Family
ID=79281595
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA58653A MA58653B1 (en) | 2020-06-26 | 2021-06-18 | USE OF A GLUTARIMIDE DERIVATIVE TO TREAT DISEASES RELATED TO ABERRANT INTERLEUKIN-6 ACTIVITY |
Country Status (6)
Country | Link |
---|---|
CN (1) | CN115803026A (en) |
BR (1) | BR112022026356A2 (en) |
CL (1) | CL2022003725A1 (en) |
CO (1) | CO2023000604A2 (en) |
MA (1) | MA58653B1 (en) |
WO (1) | WO2021262040A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023177329A1 (en) * | 2022-03-18 | 2023-09-21 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Use of 1-(2-(1н-imidazole-4-yl)ethyl)piperidine-2,6-dione to treat cough caused by viral infections |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2112716A1 (en) * | 1971-03-17 | 1972-10-05 | Thomae Gmbh Dr K | Biphenylyl-butyric acid derivs. - anti phlogistics |
DE10002509A1 (en) * | 2000-01-21 | 2001-07-26 | Gruenenthal Gmbh | New substituted glutarimide derivatives are IL-12 antagonists, are useful as immunomodulators and for the treatment of angiopathy, hematological or oncological disorders |
UA115431C2 (en) * | 2011-10-11 | 2017-11-10 | Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" | Use of glutaryl histamine to treat respiratory tract infections |
CN102432544B (en) * | 2011-11-17 | 2014-05-21 | 天津医科大学 | 5-substituted benzyl methylene imidazole alkyl-2,4-diketone derivative and application thereof |
EA032951B1 (en) * | 2013-04-12 | 2019-08-30 | Общество С Ограниченной Ответственностью "Рсв Терапевтикс" | Glutarimide derivative, use thereof, pharmaceutical composition based thereon, process for preparing same |
RU2552929C1 (en) * | 2013-11-14 | 2015-06-10 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Pharmaceutical composition, containing derivatives of glutarimides, and their application for treatment of eosinophilic diseases |
US10739353B2 (en) * | 2014-12-31 | 2020-08-11 | Signpath Pharma, Inc. | Suppression of cytokine release and cytokine storm |
GEP20227402B (en) * | 2017-09-07 | 2022-08-10 | Valenta Intellekt Ltd | Use of glutarimide derivative to treat diseases related to aberrant activity of cytokines |
AU2021257439A1 (en) * | 2020-04-13 | 2022-12-15 | University Health Network | Methods for treating cytokine release syndrome |
EP4144728A4 (en) * | 2020-04-30 | 2023-08-23 | Shanghaitech University | Heterocycle and glutarimide skeleton-based compound and applications thereof |
-
2021
- 2021-06-18 MA MA58653A patent/MA58653B1/en unknown
- 2021-06-18 BR BR112022026356A patent/BR112022026356A2/en unknown
- 2021-06-18 CN CN202180044905.7A patent/CN115803026A/en active Pending
- 2021-06-18 WO PCT/RU2021/050170 patent/WO2021262040A1/en active Application Filing
-
2022
- 2022-12-22 CL CL2022003725A patent/CL2022003725A1/en unknown
-
2023
- 2023-01-19 CO CONC2023/0000604A patent/CO2023000604A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
BR112022026356A2 (en) | 2023-01-17 |
CL2022003725A1 (en) | 2023-05-19 |
RU2020121363A (en) | 2021-12-27 |
MA58653B1 (en) | 2024-02-29 |
WO2021262040A1 (en) | 2021-12-30 |
RU2020121363A3 (en) | 2021-12-27 |
CO2023000604A2 (en) | 2023-01-26 |
CN115803026A (en) | 2023-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA202090955A1 (en) | METHODS OF USING EHMT2 INHIBITORS IN TREATMENT OR PREVENTION OF BLOOD DISORDERS | |
MA53399B1 (en) | Substituted pyrazoles as inhibitors of human plasma kallikrein | |
NO20025601D0 (en) | Arylmethylamine derivatives for use as tryptase inhibitors | |
MA40814A1 (en) | Pharmaceutical compositions for combination therapy | |
CR7882A (en) | Compounds 2- (1H-Indazol-6-ylamino-benzamides as protein kinase inhibitors useful for the treatment of ophthalmic diseases | |
HRP20050533A2 (en) | Aminoindazole derivatives and use thereof as kinase inhibitors | |
EP2329842A3 (en) | Interleukin-1 inhibitors in the treatment of diseases | |
CY1124763T1 (en) | METHOD FOR THE THERAPEUTIC TREATMENT OF PRIMARY INSOMNIA | |
TNSN07063A1 (en) | THERAPEUTIC USES OF RTP801 INHIBITORS | |
NO20052272L (en) | CCR1 antagonists for the treatment of, among other things, the demylins inflammatory disease | |
JP2005532372A5 (en) | ||
MA28435B1 (en) | INDAZOLE CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | |
MA30324B1 (en) | BENZIMIDAZOLES WITH ACTIVITY AT THE M1 RECEPTOR AND THEIR USE IN MEDICINE | |
MXPA04001187A (en) | Interleukin-1 receptors in the treatment of diseases. | |
PE20050389A1 (en) | QUINOLINE AND QUINOXALINE COMPOUNDS | |
MY172303A (en) | Compositions and methods of use of phorbol esters | |
CL2004000366A1 (en) | USE OF A COMBINATION OF A QUINASA P38 INHIBITING DERIVED COMPOUND OF PIRAZOL, AND AN ACE INHIBITOR TO TREAT RENAL DYSFUNCTION, CARDIOVASCULAR AND VASCULAR DISEASE, RETINOPATHY, NEUROPATIA, EDOTEL, INSOTUNATIO OPINION. | |
EA200600480A1 (en) | IMIDAZOPIRIDIN-SUBSTITUTE TROPANE DERIVATIVES, possessing the activity of the antagonist CCR5 Receptor, for the treatment of the human immunodeficiency virus (HIV) and inflammation | |
EA200200591A1 (en) | PYRROLIDINES THAT INHIBIT CAMP-SPECIFIC PDE | |
MA47736B1 (en) | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors | |
MA58653B1 (en) | USE OF A GLUTARIMIDE DERIVATIVE TO TREAT DISEASES RELATED TO ABERRANT INTERLEUKIN-6 ACTIVITY | |
EA200201276A1 (en) | ARYLMETYLAMINE DERIVATIVES FOR USE AS TRIPTASE INHIBITORS | |
MX2018013325A (en) | Adenine derivatives as protein kinase inhibitors. | |
EA202191150A1 (en) | AMINOPEPTIDASE A INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
EA202190398A1 (en) | CONDENSED RING DERIVATIVE USED AS FGFR4 INHIBITOR |